{"id":"W2901155618","doi":"10.1177/1352458518808189","title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial","year":2018,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"St. Michael's Hospital","funders":"Bayer HealthCare; Acorda Therapeutics","keywords":"Ocrelizumab; Medicine; Placebo; Multiple sclerosis; Physical therapy; Internal medicine; Psychiatry; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003154354,0.0007522508,0.002284192,0.000440495,0.0009752632,0.0002565793,0.0007208838,0.0002893974,0.0003635734],"category_scores_gemma":[0.00430108,0.0004152144,0.0006284827,0.0009198119,0.001938296,0.0006182074,0.0004591868,0.001319737,0.0000174428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007264341,"about_ca_system_score_gemma":0.0006406156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002376804,"about_ca_topic_score_gemma":0.00006581889,"domain_scores_codex":[0.9916704,0.001226216,0.002174631,0.000920284,0.002795587,0.001212825],"domain_scores_gemma":[0.9935248,0.00189566,0.001399668,0.0008437907,0.001759259,0.0005768436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6476765,0.00498575,0.3087389,0.00004359036,0.0007013908,0.000009880368,0.003306141,0.000003531084,0.01301407,8.146877e-7,0.001718623,0.0198008],"study_design_scores_gemma":[0.5518369,0.002973324,0.4304438,0.00327503,0.0002061537,0.00000417788,0.0004901941,0.0003951468,0.009999026,0.000005904704,0.00007418031,0.0002961785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888984,0.001255015,0.00008463066,0.0007619782,0.0006644074,0.008031687,0.0001641872,0.00007566932,0.00006404443],"genre_scores_gemma":[0.9925303,0.0007278883,0.004480558,0.0001589735,0.001100918,0.0007644599,0.0001174416,0.00009902488,0.00002045204],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1217048,"threshold_uncertainty_score":0.9998299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05233094733037293,"score_gpt":0.3083775981125121,"score_spread":0.2560466507821392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}